Fig. 6
IPN60090, a ZSWIM4-targeting inhibitor, enhances the chemotherapeutic sensitivity of EOC cells. A 3D structure of human ZSWIM4. B Structural simulation of ZSWIM4 and IPN60090. IPN60090 is depicted as a gray-white stick, with the red dashed line indicating the length of the hydrogen bond. C–D The affinity of anti-ZSWIM4 antibody C and IPN60090 D for ZSWIM4 protein determined by SPR analyses. KD, dissociation constant. E Detection of intracellular glycine content in OVCAR8 and SKOV3 cells treated with 10 μM IPN60090 for 48 h. F ROS levels in EOC cells following IPN60090 (10 μM) treatment for 48 h. G IC50 curves for OVCAR8 and SKOV3 cells following treatment with CBP and/or IPN60090 (10 μM) for 72 h. H Tumorsphere formation in OVCAR8 cells treated with vehicle control, CBP (50 μM), IPN60090 (10 μM), and CBP (50 μM) combined with IPN60090 (10 μM) for 5 day. Representative images (left) and statistical data (mean ± SD) (right) are shown. I Viability of ZSWIM4-knockdown and vector control EOC cells following treatment with CBP (25 μM) with or without IPN60090 (10 μM) for 72 h; CCK-8 assay. J–L SKOV3-derived xenograft mice were divided into four groups (n = 4/group) and administered the vehicle control, CBP (15 mg/kg, i.p.) thrice weekly, IPN60090 (30 mg/kg/day, p.o.), and CBP combined with IPN60090. Photographs of tumors J. Tumor weight K. Growth curves of xenograft tumors L